Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD146176 (NSC-168807) 是一种 15-脂氧合酶(15-LO)抑制剂,抑制兔网织红细胞 15-LO,Ki 为 197 nM,IC50 为 0.54 μM。 它通过刺激老年三重转基因小鼠的自噬来逆转认知障碍、脑淀粉样变性和 tau 病理学。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 546 | 现货 | ||
2 mg | ¥ 797 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
10 mg | ¥ 2,080 | 现货 | ||
25 mg | ¥ 3,920 | 现货 | ||
50 mg | ¥ 5,690 | 现货 | ||
100 mg | ¥ 7,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,220 | 现货 |
产品描述 | PD146176 (NSC-168807) is an inhibitor of 15-Lipoxygenase (15-LO) , it inhibits rabbit reticulocyte 15-LO with Ki of 197 nM and IC50 of 0.54 μM. PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice. |
靶点活性 | 15-LOX:IC50: 0.54 μM, 15-LOX:Ki: 197 nM |
体外活性 | 15-LO by PD146176, an inhibitor of 15-LO with an IC50 in cells or isolated enzyme of 0.5-0.8 microM, may limit atherosclerotic lesion development through regulation of monocyte-macrophage enrichment.?Rabbits exposed to chronic endothelial denudation of the iliac-femoral artery were meal-fed a 0.25% cholesterol (C), 3% peanut oil (PNO), 3% coconut oil (CNO) diet twice daily with and without 175 mg/kg PD146176 for 12 weeks.?In a second study, atherosclerotic lesions were pre-established in rabbits through chronic endothelial denudation and meal-fed a 0.5% C, 3% PNO, 3% CNO diet for 9 weeks and a 0% C/fat diet for 6 weeks prior to an 8 week administration of PD146176 at 175 mg/kg,?q.d. Plasma total and lipoprotein cholesterol exposure were similar in control and PD146176-treated animals in both studies but PD146176 increased plasma triglyceride exposure 2- to 4-fold.?Plasma PD146176 concentrations ranged from 99 to 214 ng/ml at 2 h post-dose.?In the progression study, the iliac-femoral monocyte-macrophage area was reduced 71%, cross-sectional lesion area was unchanged and cholesteryl ester (CE) content was reduced 63%.?In the regression study, size and macrophage content of iliac-femoral, fibrous plaque-like lesions were decreased 34%, CE content was reduced 19% and gross extent of thoracic aortic lesions were reduced 41%.?PD146176 can limit monocyte macrophage enrichment of atherosclerotic lesions and can attenuate development of fibrofoamy and fibrous plaque lesions in the absence of changes in plasma total or lipoprotein cholesterol concentrations[1]. |
别名 | NSC168807 |
分子量 | 237.32 |
分子式 | C15H11NS |
CAS No. | 4079-26-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (105.34 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.2137 mL | 21.0686 mL | 42.1372 mL | 105.343 mL |
5 mM | 0.8427 mL | 4.2137 mL | 8.4274 mL | 21.0686 mL | |
10 mM | 0.4214 mL | 2.1069 mL | 4.2137 mL | 10.5343 mL | |
20 mM | 0.2107 mL | 1.0534 mL | 2.1069 mL | 5.2671 mL | |
50 mM | 0.0843 mL | 0.4214 mL | 0.8427 mL | 2.1069 mL | |
100 mM | 0.0421 mL | 0.2107 mL | 0.4214 mL | 1.0534 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PD146176 4079-26-9 Apoptosis Autophagy Metabolism Ferroptosis Lipoxygenase inhibit tau PD 146176 brain triple NSC-168807 pathology amyloidosis transgenic reticulocyte impairment NSC168807 cognitive mice PD-146176 Inhibitor cells IC21 rabbit NSC 168807 inhibitor